Introduction
Insulinomas are neuroendocrine tumours (NET) derived from pancreatic beta-cells. The diagnosis is based on clinical symptoms (such as neuroglycopenic symptoms) and biochemical parameters (endogenous hyperinsulinism confirmed by hypoglycaemia). The standard treatment for insulinomas is surgical resection, requiring exact localization of the tumour lesions. Therefore, patients usually undergo computed tomography (CT) and magnetic resonance imaging (MRI) to precisely localize the primary tumour and potential metastases in those with malignant insulinoma. Somatostatin receptor scintigraphy (SRS) is considered the most sensitive method for detection of NET [1] . In contrast to other NET, the sensitivity of SRS for detecting insulinomas is only 40-60% due to the relatively low incidence of somatostatin subtype receptor (sstr) 2 and sstr5 expression in insulinomas [1] [2] [3] . Therefore, SRS is not suitable for localizing insulinomas. Recent studies have shown a high detection rate of insulinomas with endoscopic ultrasonography [4] . However, the high detection rate is limited to tumours that are located in the head and the body of the pancreas. Moreover, this technique requires specialized expertise and is observer-dependent. Angiography shows reasonable localization of insulinomas in approximately 70% of patients. However, the localization varies from 43% to 94% due to observer-dependency [5] . Arterial stimulation and venous sampling is a sensitive method that is able to localize over 90% of insulinomas [5] . The major drawback is that the procedure is invasive. Thus, there is a need for new noninvasive strategies for localization of insulinomas.
The glucagon-like peptide 1 receptor (GLP-1R) is expressed in >90% of insulinomas at a mean density twice that of sstr2 [6] . First preclinical studies have shown that 123 I-GLP-1 and 123 I-exendin-3 accumulate in rat insulinomas (RINm5F) subcutaneously implanted in NEDH rats, and that these tumours can be detected scintigraphically [7] . However, radioiodinated peptides have a relatively low uptake in vivo, due to washout of the radionuclide after internalization [8] [9] [10] [11] . Recent studies have shown high uptake of DTPAconjugated [Lys 40 ]exendin-4 labelled with 111 In in the Rip1Tag2 spontaneous insulinoma mouse model [12, 13] . Moreover, administration of a therapeutic dose of 111 Inlabelled [Lys 40 (DTPA)]exendin-4 markedly inhibited the growth of insulinomas in Rip1Tag2 mice [14] . Based on these promising results, 111 In-labelled exendin-4 has been used for the detection of insulinomas in humans by single photon emission computed tomography (SPECT) [15] . Previous studies have used exendin-3 and exendin-4, which share 95% homology (Table 1) . Exendin-3 and exendin-4 differ in two amino acids (positions 2 and 3) located in the region of the peptide that is involved in internalization of the receptor-ligand complex, which might lead to differences in biodistribution of these peptides. In this study we therefore compared the biodistribution of [Lys In. Because even small insulinomas may induce clinical symptoms, imaging methods for the detection of these tumours needs to be highly sensitive. Positron emission tomography (PET) may therefore offer an advantage over SPECT because of its excellent sensitivity in combination with its improved spatial resolution. As the radionuclide for PET imaging of GLP-1Rs with exendin, 68 Ga seems to be the optimal candidate since DOTA-conjugated probes can be rapidly and efficiently labelled with 68 Ga, and because 68 Ga is a generator-produced positron emitter, it is widely available and relatively cheap. In was added to 1 µg peptide followed by five volumes of 0.1 M MES buffer, pH 5.5, resulting in a total volume of reaction mixture ranging from 800 µl to 2,345 µl. After incubation at room temperature for 30 min, quality control was performed using reversed-phase high-performance liquid chromatography (RP-HPLC) on a C 18 reversed-phase column (Zorbax Rx-C18; 4.6 mm× 25 cm; Agilent Technologies) and instant thin-layer chroma-
Peptide
Amino acid sequence Exendin-3 HSDGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 Exendin-4 HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPPS-NH2 The final pH of the reaction mixture was 3.0. The mixture was incubated at 95°C for 15 min, then EDTA was added to a final concentration of 5 mM, and the mixture was incubated at room temperature for 5 min. The reaction mixture was purified by HPLC using a C 8 reversed-phase column (Zorbax eclipse XDB C 8 4.6×150 mm, 5 µm; Agilent Technologies). The column was eluted with 10 mM ammonium acetate, pH 5.5 (0-5 min) and 40% ethanol (5-10 min) followed by a linear gradient from 40% to 90% ethanol over 5 min (flow rate 1 ml/min). The fractions containing [Lys 40 ( 68 Ga-DOTA)] exendin-3 were collected and diluted with PBS containing 0.5% BSA to a final ethanol concentration of less than 10% before injection into mice (injection volume 0.2 ml). The contents of unincorporated 68 Ga and 68 Ga colloid in the purified 68 Ga-labelled [Lys40(DOTA)]exendin-3 preparations were determined using ITLC as described above.
Cell culture
The rat insulinoma cell line INS-1 [16] was maintained in RPMI-1640 medium supplemented with 10% fetal bovine serum, 2 mM glutamine, 10 mM HEPES, 50 µM β-mercaptoethanol, 1 mM sodium pyruvate, 100 U/ml penicillin and 100 µg/ml streptomycin, in a humidified atmosphere containing 5% CO 2 at 37°C. The cells were harvested by trypsinization with trypsin/EDTA. In-DTPA)]exendin-3 (60,000 dpm). To prevent internalization, cells were incubated on ice for 4 h. The cell suspension was centrifuged at 3,000 g for 5 min and the supernatant was discarded. The cells were washed twice with ice-cold PBS, centrifuged, and the radioactivity in the cell pellet was determined in a gamma-counter (Wizard, Wallac-Oy, Uppsala, Sweden), and the bound fraction was determined.
In vitro internalization
The kinetics of internalization of [Lys 40 ( 111 In-DTPA)] exendin-3 were determined as described previously [17] . INS-1 cells were seeded at a density of 500,000 cells/well in six-well plates and incubated overnight at 37°C. The cells were washed twice with binding buffer and subsequently incubated at 37°C for 10 min in 1.0 ml binding buffer. Approximately 60,000 dpm of 111 In-labelled peptide (55 fmol) was added followed by incubation for 0.5, 1, 2 or 4 h at 37 C. To determine nonspecific binding, 1 µg unlabelled [Lys 40 ]exendin-3 was added together with the 111 In-labelled peptide to three wells per time point. After incubation, the cells were washed twice with binding buffer. To determine the surface-bound radiolabelled peptide, ice-cold acid buffer (0.1 M acetic acid, 154 mM NaCl, pH 2.5) was added and cells were incubated for 10 min at 4°C. After washing the cells twice with binding buffer, they were harvested with a cotton stick and the cell-associated activity was measured in a gamma-counter. The internalized fraction (cell-associated activity after acid wash) and the receptor-bound fraction (activity removed by acid wash) were determined. The PET images were acquired over 45 min for the emission scan, and the images were reconstructed by OSEM3D/MAP reconstruction. 8%ID/g, p<0.001) .
Results

Radiolabelling
In contrast to the RP-HPLC-purified preparation, [Lys 40 ( 68 Ga-DOTA)]exendin-3 purified by gel filtration on a Sephadex G-25 column showed enhanced uptake in the spleen and liver (16.8 ±0.9%ID/g and 20.9 ±1.6%ID/ g, respectively). This enhanced hepatic and splenic uptake was not receptor-mediated as it could not be blocked by coinjection of an excess of unlabelled [Lys 40 ] exendin (data not shown).Very low uptake in the liver and spleen was observed when RP-HPLC-purified [Lys 40 ( 68 Ga-DOTA)]exendin-3 was injected (0.44 ± 0.05%ID/g and 0.25 ± 0.02%ID/g, respectively). Again, no specific uptake was observed in the liver and spleen as determined by coadministration of an excess of unlabelled exendin (0.31 ± 0.02%ID/g and 0.20 ± 0.01%ID/g, respectively).
Peptide dose escalation study
The effect of the exendin-3 dose on the biodistribution in mice with subcutaneous INS-1 tumours was studied in a peptide dose escalation study. The results of this study are summarized in Fig. 7 8 and 9 ). The PET images were fused with CT images. As well as high uptake in tumour, uptake was also seen in the kidneys. PET images following injection with unpurified [Lys 40 ( 68 Ga-DOTA)]exendin-3 showed high uptake in the liver (Fig. 8c) . Despite the high liver uptake tumours were still clearly visible.
Discussion
SRS, the standard method for imaging of NET, detects only around 50% of insulinomas [1, 2, 12] . Clinical studies with 18 F-DOPA PET for the detection of insulinomas have shown promising results [18] . However, physiological uptake of 18 [12, 13] . Wild et al. demonstrated that in vivo imaging of insulinomas by SPECT with radiolabelled exendin is feasible in patients [15] . In a transgenic mouse model, they detected insulinomas of less than 1 mm in diameter using [Lys 40 ( 111 In-DTPA)]exendin-4 as tracer. Although SPECT has a higher resolution in small-animal imaging, for clinical imaging PET offers a higher spatial resolution, a higher sensitivity and the possibility to accurately quantify uptake, which makes it preferable to SPECT. Recent studies have shown that PET imaging of NET with 68 Ga-labelled octreotide is superior to SPECT imaging with 111 In-labelled octreotide [19, 20] .
In this study we therefore investigated the potential of [Lys 40 ( 68 Ga-DOTA)]exendin-3 for the detection of insulinomas by PET in a mouse model. Conjugation of [Lys 40 ] exendin-3 with DOTA instead of DTPA allows radiolabelling of the tracer with a broad range of radionuclides including the positron emitter 68 Ga. We selected 68 Ga as positron emitter because it is a generator-derived radionuclide (and therefore readily available), the labelling strategy is fast and relatively simple, and the half-life matches the pharmacokinetics of the tracer (exendin) [13] . A potential 68 Ga for animal imaging may be the high energy of the emitted β + particles limiting the spatial resolution of the images to 3 mm while the intrinsic resolution of the scanner is 1.5 mm [21] . This is only a relevant issue in preclinical scanners, as in clinical scanners the intrinsic resolution of the scanner rather than the β + energy will limit the resolution of the images.
Biodistribution studies in BALB/c nude mice with subcutaneous INS-1 tumours showed high and specific uptake of [ Enhanced uptake of [Lys 40 ( 68 Ga-DOTA)]exendin-3 was seen in the liver and spleen when the preparation was only purified by gel filtration, probably because this preparation still contained some colloidal 68 Ga. Colloidal 68 Ga will accumulate in the liver and spleen. RP-HPLC purification removed the colloidal contamination, since this preparation had the same very low uptake in the liver and spleen as the 111 In-labelled preparation. Previous studies with 68 Galabelled DOTA-conjugated compounds not purified by RP-HPLC have also shown enhanced liver and spleen uptake [23, 24] . It is still a matter of debate whether the enhanced uptake in liver and spleen is caused by colloidal 68 Ga or by instability of the 68 Ga-DOTA complex. In the present study, uptakes of HPLC-purified [Lys 40 ( 68 Ga-DOTA)]exendin-3 in the liver and spleen were identical to that of 111 In-labelled exendin-3. Our data suggest that the enhanced uptake in the liver and spleen of 68 Ga-labelled compounds found in previous studies is not caused by instability of the 68 Ga-DOTA complex but by minor amounts of colloid.
To obtain high-quality PET images a 68 Ga activity of 3 MBq was required. This necessitated the administration of an exendin dose of 0.3 µg, and although this resulted in suboptimal uptake (as demonstrated in the peptide dose escalation study), the tumours could exactly be visualized.
GLP-1R is also expressed on native pancreatic betacells. Radiolabelled exendin can potentially be used to target beta-cells. This is an attractive approach for the determination of beta-cell mass, a key issue in diabetes mellitus. [Lys 40 ( 111 In-DTPA)]exendin and [Lys 40 ( 68 Ga-DOTA)]exendin potentially can be used to noninvasively determine the beta-cell mass in the pancreas by SPECT or PET. A previous study has shown a correlation between the uptake of 111 In-labelled exendin and the beta-cell mass [25] , which makes this approach promising for the in vivo determination of the beta-cell mass.
In 
